Clinical blood pool MR imaging

Clinical blood pool MR imaging / , Clinical blood pool MR imaging / , کتابخانه دیجیتال جندی شاپور اهواز

[1]  W. Heindel,et al.  First‐pass and equilibrium‐MRA of the aortoiliac region with a superparamagnetic iron oxide blood pool MR contrast agent (SH U 555 C): results of a human pilot study , 2004, NMR in biomedicine.

[2]  Debiao Li,et al.  Contrast-enhanced MR imaging of coronary arteries: comparison of intra- and extravascular contrast agents in swine. , 2001, Radiology.

[3]  Peter Caravan,et al.  Species Dependence on Plasma Protein Binding and Relaxivity of the Gadolinium-Based MRI Contrast Agent MS-325 , 2006, Investigative radiology.

[4]  J. Mintorovitch,et al.  Comparison of Magnetic Properties of MRI Contrast Media Solutions at Different Magnetic Field Strengths , 2005, Investigative radiology.

[5]  S. Schoenberg,et al.  Vasovist-enhanced MR angiography , 2006, European radiology.

[6]  S. Schoenberg,et al.  High-spatial-resolution multistation MR angiography with parallel imaging and blood pool contrast agent: initial experience. , 2006, Radiology.

[7]  Jayaram K. Udupa,et al.  Artery-vein separation via MRA-An image processing approach , 2001, IEEE Transactions on Medical Imaging.

[8]  M. Knopp,et al.  Assessment of Utilization and Pharmacovigilance Based on Spontaneous Adverse Event Reporting of Gadopentetate Dimeglumine as a Magnetic Resonance Contrast Agent After 45 Million Administrations and 15 Years of Clinical Use , 2006, Investigative radiology.

[9]  Yoshimi Anzai,et al.  MR angiography with an ultrasmall superparamagnetic iron oxide blood pool agent , 1997, Journal of magnetic resonance imaging : JMRI.

[10]  R. Muller,et al.  Paramagnetic liposomes as magnetic resonance imaging contrast agents. Assessment of contrast efficacy in various liver models. , 1998, Investigative radiology.

[11]  R. Lauffer,et al.  Preclinical evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool agent for magnetic resonance imaging. , 1997, Investigative radiology.

[12]  R. Lauffer,et al.  Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. , 1999, Chemical reviews.

[13]  A. Nunn,et al.  Can receptors be imaged with MRI agents? , 1997, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[14]  B. Misselwitz,et al.  Interstitial Magnetic Resonance Lymphography Using a Polymeric T1 Contrast Agent: Initial Experience With Gadomer-17 , 2002, Investigative radiology.

[15]  V. Jacques,et al.  New Classes of MRI Contrast Agents , 2002 .

[16]  Nicolaas Bloembergen,et al.  Proton Relaxation Times in Paramagnetic Solutions. Effects of Electron Spin Relaxation , 1961 .

[17]  S. F. Quinn,et al.  Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of gadofosveset-enhanced MR angiography--multicenter comparative phase III study. , 2005, Radiology.

[18]  L. Calabi,et al.  The problematic determination of proton magnetic relaxation rates of protein-containing solutions. , 2002, Academic radiology.

[19]  J Lautrou,et al.  Physicochemical and biological evaluation of P792, a rapid-clearance blood-pool agent for magnetic resonance imaging. , 2001, Investigative radiology.

[20]  M. Port,et al.  P792: a rapid clearance blood pool agent for magnetic resonance imaging: preliminary results , 2001, Magnetic Resonance Materials in Physics, Biology and Medicine.

[21]  B. Rutt,et al.  Comparison of two blood pool contrast agents for 0.5-T MR angiography: experimental study in rabbits. , 2000, Radiology.

[22]  B. Hamm,et al.  Phase I Clinical Evaluation of Citrate-coated Monocrystalline Very Small Superparamagnetic Iron Oxide Particles as a New Contrast Medium for Magnetic Resonance Imaging , 2004, Investigative radiology.

[23]  I. Bertini,et al.  Nuclear and Electron Relaxation: The Magnetic Nucleus-Unpaired Electron Coupling in Solution , 1991 .

[24]  Wolfgang Ebert,et al.  Pharmacokinetics of Gadomer-17, a new dendritic magnetic resonance contrast agent , 2001, Magnetic Resonance Materials in Physics, Biology and Medicine.

[25]  A. Bjørnerud,et al.  NC100150 injection, a preparation of optimized iron oxide nanoparticles for positive‐contrast MR angiography , 2000, Journal of magnetic resonance imaging : JMRI.

[26]  Tim Leiner,et al.  Maximizing contrast‐to‐noise ratio in ultra‐high resolution peripheral MR angiography using a blood pool agent and parallel imaging , 2007, Journal of magnetic resonance imaging : JMRI.

[27]  A. Wiethoff,et al.  Initial imaging recommendations for Vasovist angiography , 2006, European radiology.

[28]  Peter Caravan,et al.  The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. , 2002, Journal of the American Chemical Society.

[29]  Weissleder,et al.  Approaches and agents for imaging the vascular system. , 1999, Advanced drug delivery reviews.

[30]  R. Lauffer,et al.  Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design , 1987 .

[31]  D C Peters,et al.  Steady-state and dynamic MR angiography with MS-325: initial experience in humans. , 1998, Radiology.

[32]  R. Lauffer,et al.  Targeted relaxation enhancement agents for MRI , 1991, Magnetic resonance in medicine.

[33]  I. Bertini,et al.  NMR of paramagnetic substances , 1996 .

[34]  M. Port,et al.  How to Compare the Efficiency of Albumin-Bound and Nonalbumin-Bound Contrast Agents In Vivo: The Concept of Dynamic Relaxivity , 2005, Investigative radiology.

[35]  T. Steger-Hartmann,et al.  Preclinical Safety Assessment of Vasovist (Gadofosveset trisodium), a New Magnetic Resonance Imaging Contrast Agent for Angiography , 2006, Investigative radiology.